Sugi Predict

Sugi Predict / Compounds / SCHEMBL6626077

SCHEMBL6626077

SCHEMBL6626077

CCCC(CNc1cc(OC)c2ccccc2n1)CN[C@@H](Cc1ccccc1)c1c[nH]c2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.48
▸ GPR84 Q9NQS5 2/20 0.40
▸ FFAR1 O14842 1/20 0.40
▸ P2RY12 Q9H244 2/20 0.37
▸ MAPT P10636 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ EGFR P00533 2/20 0.33
▸ KDR P35968 2/20 0.33
▸ ADRB3 P13945 1/20 0.33
▸ CYP2D6 P10635 2/20 0.32
▸ NR3C1 P04150 1/20 0.32
▸ PGR P06401 1/20 0.32
▸ NR3C2 P08235 1/20 0.32
▸ AR P10275 1/20 0.32
▸ SLC6A2 P23975 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6620238 1.00 SLC2A1 (0.48) SLC2A1GPR84FFAR1P2RY12MAPT
SCHEMBL6620235 1.00 SLC2A1 (0.48) SLC2A1GPR84FFAR1P2RY12MAPT
SCHEMBL6619599 0.94 SLC2A1 (0.52) SLC2A1GPR84FFAR1P2RY12MAPT
SCHEMBL6621344 0.88 SLC2A1 (0.51) SLC2A1GPR84P2RY12MAPTNPSR1
SCHEMBL6621908 0.86 SLC2A1 (0.49) SLC2A1GPR84P2RY12MAPTNPSR1
SCHEMBL6618356 0.86 SLC2A1 (0.49) SLC2A1GPR84P2RY12MAPTNPSR1
SCHEMBL6624640 0.86 SLC2A1 (0.49) SLC2A1GPR84P2RY12MAPTNPSR1
SCHEMBL6620305 0.84 SLC2A1 (0.42) SLC2A1P2RY12NPSR1MEN1KMT2A
SCHEMBL6618769 0.84 SLC2A1 (0.47) SLC2A1GPR84P2RY12MAPTNPSR1
SCHEMBL6618499 0.82 SLC2A1 (0.48) SLC2A1GPR84P2RY12MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818655-B2 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM CORPORATION 2004-11-16 — — US claimed
EP-1359915-A4 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM (US) 2004-07-21 — — EP claimed
US-20040063757-A1 Urotensin-ll receptor antagonists SMITHKLINEE BEECHAM CORPORATION 2004-04-01 — — US claimed
EP-1359915-A1 UROTENSIN-II RECEPTOR ANTAGONISTS Smithkline Beecham (US) 2003-11-12 — — EP claimed
WO-2002058702-A1 UROTENSIN-II RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (GB) 2002-08-01 — — WO claimed
US-6818655-B2 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM CORPORATION 2004-11-16 — — US disclosed
US-20040063757-A1 Urotensin-ll receptor antagonists SMITHKLINEE BEECHAM CORPORATION 2004-04-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063757-A1 Urotensin-ll receptor antagonists UTS2R, PLAUR, SCTR SLC2A1 3284/4885GPR84 53/4885FFAR1 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.